Company Overview of Horizon Pharma USA, Inc.
Horizon Pharma USA, Inc. develops prescription drugs for mild to moderate pain relief and arthritis. The company's products include HZT-501, a proprietary fixed dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Pharma USA, Inc. was formerly known as Horizon Therapeutics, Inc. and changed its name to Horizon Pharma USA, Inc. in April 2010. The company was founded in 2005 and is based in Deerfield, Illinois. Horizon Pharma USA, Inc. operates as a subsidiary of Horizon Pharma plc.
520 Lake Cook Road
Deerfield, IL 60015
Founded in 2005
Key Executives for Horizon Pharma USA, Inc.
Horizon Pharma USA, Inc. does not have any Key Executives recorded.
Horizon Pharma USA, Inc. Key Developments
Horizon Announces Proposes Private Offering of Senior Notes
Oct 13 16
Horizon Pharma plc announced that Horizon Pharma, Inc. and Horizon Pharma USA, Inc., its wholly owned subsidiaries, intend, subject to market and other considerations, to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million aggregate principal amount of incremental term loans under Horizon’s existing senior secured credit facility. Horizon currently expects to use the net proceeds from the offering of notes and the incremental term loans to fund a portion of Horizon’s planned acquisition of Raptor Pharmaceutical Corp., repay Raptor’s outstanding debt, and pay any prepayment premiums, fees and expenses in connection with the foregoing. The notes and the incremental term loans will be fully and unconditionally guaranteed by Horizon, as well as by certain of its existing and future subsidiaries. The notes will be offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended and to non-U.S. buyers in accordance with Regulation S under the Securities Act. The notes have not been and are not expected to be registered under the Securities Act or under any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
Express Scripts Wins $65 Million Settlement from Horizon Pharma USA, Inc
Sep 29 16
Horizon Pharma USA, Inc. announced that it will pay $65 million to Express Scripts in a settlement over litigation that began in November. Express Scripts sued Horizon Pharma then for breach of contract, seeking $166.2 million in rebates relating to Horizon Pharma's Duexis, Rayos and Vimovo medicines. Express Scripts said then that it was taking aim at 'captive' pharmacies that are aimed at pushing a single manufacturer's products. Express Scripts alleged that Linden Care, a specialty pharmacy in Woodbury, New York, dispensed mostly products made by Horizon Pharma. Horizon Pharma contested that claim, and said the amount owed under the rebate agreement was wrong and that Express Scripts breached their agreement. The suit was filed in a Delaware court. Horizon Pharma said 50% of the settlement would be paid in the fourth quarter of 2016, 25% in the first quarter of 2017 and 25% in the second quarter of 2017.
Horizon Pharma plc Proposes Private Offering of Senior Notes and Intention to Enter into New Term Loan Facility
Apr 20 15
Horizon Pharma plc announced that Horizon Pharma Financing Inc. to offer $300 million aggregate principal amount of senior notes due 2023, and that Horizon Pharma Inc. intends to enter into a new term loan facility in an aggregate principal amount of $500 million. Horizon currently expects to use the net proceeds from the offering of notes and borrowings under the new term loan facility to fund a portion of Horizon's planned acquisition of Hyperion Therapeutics Inc., repay the outstanding amounts under Horizon's existing $300 million credit facility and certain outstanding debt of Hyperion, and pay any prepayment premiums, fees and expenses in connection with the foregoing. The proceeds from the offering of the notes will be held in escrow pending release in connection with the closing of the Hyperion acquisition. The notes will be offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended and to non-U.S. buyers in accordance with Regulation S under the Securities Act.
Similar Private Companies By Industry
Recent Private Companies Transactions